Breaking News Instant updates and real-time market news.

NRG

NRG Energy

$32.79

0.29 (0.89%)

, IQV

Iqvia

$121.25

0.45 (0.37%)

11:24
08/14/18
08/14
11:24
08/14/18
11:24

Cooperman's Omega buys NRG and Iqvia in Q2, sells out of Netflix

Leon Cooperman's Omega Advisors disclosed in an SEC filing its holdings as of June 30, 2018. Omega's 27 new buys during the second quarter included, by size of position, NRG Energy (NRG), Iqvia Holdings (IQV), Lennar (LEN), Marathon Petroleum (MPC) and CVS Health (CVS). Omega exited 27 positions during the quarter, including by size of previous position, Bristol-Myers Squibb (BMY), Wells Fargo (WFC), Navient (NAVI), Netflix (NFLX) and New York Community Bancorp (NYB). Omega increased its stake in 18 holdings, including by size of increase, Sinclair Broadcast (SBGI), Humana (HUM), Trinity Industries (TRN), Citi (C) and FTS International (FTSI). Omega reduced its stake in 28 holdings, including Shire (SHPG), Andeavor (ANDV), MaxLinear (MXL), PVH Corp. (PVH) and Dish (DISH). Omega's top holdings as of June 30, in order of size, were United Continental (UAL), Alphabet (GOOGL), AMC Networks (AMCX), First Data (FDC) and Microsoft (MSFT).

NRG

NRG Energy

$32.79

0.29 (0.89%)

IQV

Iqvia

$121.25

0.45 (0.37%)

LEN

Lennar

$51.45

0.64 (1.26%)

MPC

Marathon Petroleum

$80.25

0.16 (0.20%)

CVS

CVS Health

$71.17

1.66 (2.39%)

BMY

Bristol-Myers

$59.95

0.53 (0.89%)

WFC

Wells Fargo

$57.99

0.35 (0.61%)

NAVI

Navient

$13.13

0.1 (0.77%)

NFLX

Netflix

$338.98

-2.3 (-0.67%)

NYB

New York Community Bancorp

$0.00

(0.00%)

SBGI

Sinclair Broadcast

$28.45

0.6 (2.15%)

HUM

Humana

$329.23

5.245 (1.62%)

TRN

Trinity Industries

$37.42

0.06 (0.16%)

C

Citi

$69.79

0.66 (0.95%)

FTSI

FTS International

$12.16

0.09 (0.75%)

SHPG

Shire

$169.65

-0.13 (-0.08%)

ANDV

Andeavor

$149.29

0.45 (0.30%)

MXL

MaxLinear

$19.19

0.05 (0.26%)

PVH

PVH Corp.

$153.26

0.02 (0.01%)

DISH

Dish

$35.50

0.5 (1.43%)

UAL

United Continental

$82.15

0.89 (1.10%)

GOOG

Alphabet

$1,234.94

-0.16 (-0.01%)

GOOGL

Alphabet Class A

$1,249.88

1.12 (0.09%)

AMCX

AMC Networks

$61.11

1.12 (1.87%)

FDC

First Data

$24.18

0.28 (1.17%)

MSFT

Microsoft

$109.40

1.16 (1.07%)

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 16

    Aug

  • 16

    Aug

  • 19

    Aug

  • 22

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 12

    Sep

  • 15

    Oct

  • 28

    Oct

  • 29

    Oct

  • 21

    Dec

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

  • 14

    Aug

NRG NRG Energy
$32.79

0.29 (0.89%)

07/30/18
SBSH
07/30/18
DOWNGRADE
Target $33
SBSH
Neutral
NRG Energy downgraded to Neutral from Buy at Citi
Citi analyst Praful Mehta downgraded NRG Energy to Neutral while raising his price target for the shares to $33 from $20. The analyst cites valuation for the downgrade but continues to like NRG's business model and low leverage.
05/23/18
BOFA
05/23/18
INITIATION
Target $37
BOFA
Buy
NRG Energy resumed with a Buy, $37 target at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith resumed coverage of NRG Energy with a Buy rating and $37 price target. The analyst notes NRG's $500M convertible debt note was paired with the completion of a "meaningful portion" of the company's $500M repurchase program, half the $1B expected in 2018. Execution of these buybacks will likely lift the share price in the near-term, Dumoulin-Smith tells investors in a research note. The analyst sees "meaningful upside" in NRG shares as Electric Reliability Council of Texas forwards "continue to climb" in 2018 and 2019.
08/06/18
SBSH
08/06/18
UPGRADE
SBSH
Buy
NRG Energy upgraded to Buy from Neutral at Citi
08/06/18
SBSH
08/06/18
UPGRADE
Target $38
SBSH
Buy
Citi brings NRG Energy back to Buy a week after downgrade
Citi analyst Praful Mehta upgraded NRG Energy to Buy from Neutral and raised his price target for the shares to $38 from $33. The analyst downgraded the shares to Neutral on July 30. In a research note partially titled "We Were Wrong. Story Stronger," Mehta says the strength of NRG's model was shown in last week's Q2 report. The analyst boosted his 2019 EBITDA estimate by $300M and 2020 estimate by $150M. He views his sum-of-the-parts valuation of $38 per share as conservative since it includes no value for buybacks or return on excess cash. NRG's "strong execution and ERCOT tightness" drives the upgrade back to Buy, Mehta tells investors in a research note.
IQV Iqvia
$121.25

0.45 (0.37%)

08/13/18
WELS
08/13/18
NO CHANGE
Target $140
WELS
Outperform
Iqvia price target raised to $140 from $120 at Wells Fargo
Wells Fargo analyst Jamie Stockton raised his price target for Iqvia to $140 from $120 following a June quarter beat. The analyst reiterates an Outperform rating on the shares.
07/25/18
RHCO
07/25/18
NO CHANGE
Target $140
RHCO
Buy
Iqvia price target raised to $140 from $130 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Iqvia to $140 and kept his Buy rating after its "beat and raise" Q2. The analyst says the quarter produced evidence of top-line synergies, which is incremental to his already bullish outlook calling for "solid organic mid-single digit top-line growth with margin expansion", along with cost synergies post-IMS merger and excess capital deployment. Draper believes that Q2 beat also implies upside potential going forward on strong R&D segment bookings.
07/25/18
MSCO
07/25/18
NO CHANGE
Target $130
MSCO
Overweight
Iqvia price target raised to $130 from $121 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said Iqvia's "beat and raise" quarterly report increased his confidence that a growth inflection point will be reached in the second half of 2019. Following the report, Goldwasser raised his 2018 and 2019 revenue and EPS estimates for Iqvia and increased his price target on the shares to $130. He keeps an Overweight rating on the name.
07/25/18
JPMS
07/25/18
NO CHANGE
Target $135
JPMS
Overweight
Iqvia price target raised to $135 from $120 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Iqvia to $135 citing the company's "strong" Q2 results. Broad-based momentum points to an attractive second half of the year setup for the shares, Peterson tells investors in a research note. He maintains an Overweight rating on Iqvia.
LEN Lennar
$51.45

0.64 (1.26%)

08/07/18
MZHO
08/07/18
DOWNGRADE
Target $31
MZHO
Neutral
PulteGroup downgraded to Neutral from Buy at Mizuho
Mizuho analyst Haendel St. Juste downgraded PulteGroup (PHM) to Neutral and lowered his price target for the shares to $31 from $36. The analyst sees an "imbalanced risk/reward" profile for the shares with a lack of near-term catalysts. PulteGroup's valuation is "richer" and its 2019 earnings slower relative to peers, St. Juste tells investors in a research note. The analyst remains constructive on housing/homebuilders and favors shares of Lennar (LEN) and Toll Brothers (TOL).
06/27/18
MKMP
06/27/18
NO CHANGE
Target $71
MKMP
Buy
Lennar Q2 beat on all operating metrics, says MKM Partners
MKM Partners analyst Megan McGrath keeps her Buy rating and $71 price target on Lennar after its "impressive" Q2 results marked the first reported quarter following the acquisition of CalAtlantic. The analyst notes that the company beat on all the operating metrics - orders, closings, and margins - while continuing to see solid demand despite higher mortgage rates. McGrath anticipates continued near- and longer-term positives from Lennar's acquisition of CalAtlantic, benefiting through its larger local scale.
06/27/18
LEHM
06/27/18
NO CHANGE
Target $65
LEHM
Overweight
Lennar price target cut to $65 from $72 at Barclays
Barclays analyst Matthew Bouley maintained an Overweight rating on Lennar but cut his price target to $65 from $72, telling investors in a research note that the company's Q2 results serve as a favorable checkup on underlying demand trends, synergy progress and cash flow potential, with each of these demonstrating upside to prior estimates. Bouley says he views Lennar as well- positioned for continued non-cycle dependent upward earnings revisions -- synergies, boosting CAA absorptions and potential buybacks.
06/27/18
RBCM
06/27/18
INITIATION
Target $66
RBCM
Outperform
Lennar assumed with an Outperform at RBC Capital
RBC Capital analyst Michael Dahl assumed Lennar with an Outperform rating and a price target of $66, saying the company is positioned to drive above-market growth and margin improvement as a result of its integration with CalAtlantic. Dahl notes that the stock price has pulled back sharply on one-time integration costs and concerns around the impact of rising rates on the housing sector, but believes this presents a buying opportunity ahead of the "robust" FY19 earnings ramp.
MPC Marathon Petroleum
$80.25

0.16 (0.20%)

08/02/18
MZHO
08/02/18
INITIATION
Target $158
MZHO
Neutral
Andeavor initiated with a Neutral at Mizuho
Mizuho analyst Paul Sankey started Andeavor (ANDV) with a Neutral rating and $158 price target. The analyst believes Andeavor shares are pegged to Marathon Petroleum's (MPC) offer of 1.87 Marathon share or $152 cash.
05/29/18
05/29/18
UPGRADE
Target $113

Outperform
Marathon Petroleum upgraded to Outperform from at Wells Fargo
As previously reported, Wells Fargo analyst Roger Read upgraded Marathon Petroleum to Outperform from Market Perform and raised his price target on the shares to $113 from $80. The analyst says the IMO 2020 low sulfur marine fuel rule in his estimation will be a positive for the U.S. Independent Refiners and believes possesses the most potential upside.
08/01/18
MZHO
08/01/18
INITIATION
Target $95
MZHO
Buy
Marathon Petroleum initiated with a Buy at Mizuho
Mizuho initiated Marathon Petroleum with a Buy and $95 price target.
05/29/18
WELS
05/29/18
UPGRADE
WELS
Outperform
Marathon Petroleum upgraded to Outperform from Market Perform at Wells Fargo
CVS CVS Health
$71.17

1.66 (2.39%)

08/09/18
RBCM
08/09/18
NO CHANGE
Target $90
RBCM
Outperform
CVS Health price target raised to $90 from $84 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $90 and kept his Outperform rating after its Q2 results. The analyst notes that the quarter benefited from expense timing, given that its FY18 outlook has been largely maintained. Hill also maintains his positive outlook on the Aetna (AET) transaction and the impact of regulatory changes on the company.
08/09/18
LEER
08/09/18
NO CHANGE
Target $80
LEER
Outperform
CVS Health price target lowered to $80 form $85 at Leerink
Leerink analyst David Larsen lowered his price target for CVS Health to $80 from $85 as he remains disappointed by the 2018 Retail margin guide. Nonetheless, the analyst is encouraged by CVS' good performance this quarter and increased FY18 guidance, and by the impressive growth in Retail SS Rx volumes. Larsen reiterates an Outperform rating on the shares.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $77
PIPR
Overweight
CVS rollout could drive upside to Teladoc estimates, says Piper Jaffray
Piper Jaffray analyst Sean Wieland believes CVS Health's (CVS) expanded telehealth offering could drive upside to revenue estimates in fiscal 2019 and beyond for its partner Teladoc (TDOC). Rolling out MinuteClinic to CVS's mobile app through Teladoc is "another sign of an inflection point that telemedicine is going mainstream," Wieland tells investors in a research note. The analyst reiterates an Overweight rating on Teladoc with a $77 price target.
07/09/18
SBSH
07/09/18
UPGRADE
Target $81
SBSH
Buy
CVS Health assumed to Buy from Neutral at Citi
Citi analyst Ralph Giacobbe upgraded CVS Health (CVS) to Buy after assuming coverage of the name. The analyst raised his price target for the shares to $81 from $68. While the execution of an integrated healthcare superstore post the pending Aetna (AET) acquisition may be a long way off, the concept will resonate with employers and individuals, Giacobbe tells investors in a research note. He believes deal integration and competitive Amazon (AMZN) risk are "somewhat overstated particularly in the context of heavily discounted valuation."
BMY Bristol-Myers
$59.95

0.53 (0.89%)

08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities
08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/23/18
BMOC
07/23/18
NO CHANGE
Target $51
BMOC
Market Perform
Bristol-Myers price target raised to $51 from $47 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Bristol-Myers to $51, saying the company's Opdivo+Yervoil will likely top consensus thanks to "good growth" in the U.S. markets and that the Eliquis RX trends were likely "remarkably strong". The analyst further states that the stock price should respond positively to the likely earnings beat and may lead to some "takeout speculation", particularly if the sustainability of its immuno-oncology franchse is made clearer. Arfaei also keeps his Market Perform rating, adding that at current price levels, risk-reward is not favorable for the stock.
WFC Wells Fargo
$57.99

0.35 (0.61%)

07/20/18
OPCO
07/20/18
NO CHANGE
OPCO
Perform
Wells Fargo's next few earnings reports likely to be 'choppy,' says Oppenheimer
Oppenheimer analyst Chris Kotowski maintained a Perform rating on Wells Fargo (WFC) after recent meetings with CFO John Shrewsberry. In a research note to investors, Kotowski says there was nothing that shakes his view that the next few quarterly earnings reports are likely to still be "choppy," and notes that Shewsberry "readily acknowledged" that there was much work to be done to get the consent order lifted. At the same time, the analyst contends that shares are not trading at much of a discount versus other high performing banks like JPMorgan (JPM) and PNC (PNC) and says he favors companies that have lower but rising ROTCEs that are trading near TBV, especially Citi (C), CIT (CIT) and Goldman (GS).
07/16/18
BMOC
07/16/18
NO CHANGE
Target $61
BMOC
Market Perform
Wells Fargo price target raised to $61 at BMO Capital after in-line Q2
BMO Capital analyst James Fotheringham kept his Market Perform rating and nudged his price target on Wells Fargo (WFC) to $61 from $59 after the company's in-line Q2 "core" results which also showed higher than expected net interest margins and lower loss provisions. The analyst notes that after relative underperformance by the financials sector this year, he would recommend that investors buy "inexpensive stocks with near-term catalysts", including Santander (SC), OneMain (OMF), and Synchony (SYF).
07/15/18
KBWI
07/15/18
UPGRADE
Target $63
KBWI
Outperform
Wells Fargo upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Wells Fargo to Outperform and raised his price target for the shares to $63 from $57. The stock closed Friday down 67c to $55.36. Current share levels offer an attractive entry point for a "self-help stock" that can generate "material" earnings growth near-term, Kleinhanzl tells investors in a research note. The analyst saw enough in Wells Fargo's most recent quarter to get him more constructive. He raised his earnings estimates and sees additional upside if management can drive expenses toward the company's investor day simulation range of $50B-$51B in 2020. Kleinhanzl sees expense saves and capital returns driving shares of Wells Fargo higher.
07/16/18
07/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying current share levels offer an attractive entry point for a "self-help stock" that can generate "material" earnings growth near-term. 2. VF Corp. (VFC) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss saying he sees an attractive risk/reward profile at current share levels given the company's "multi-year inflection." 3. UPS (UPS) upgraded to Buy from Neutral at UBS with analyst Thomas Wadewitz saying the combination of cost and productivity improvements, coupled with a constructive" revenue backdrop, provide potential for improved Domestic Package margin performance and stronger operating income growth in 2019 for UPS. 4. Autoliv (ALV) upgraded to Outperform from Neutral at Daiwa. 5. Saratoga Investment (SAR) upgraded to Buy from Neutral at Compass Point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NAVI Navient
$13.13

0.1 (0.77%)

06/01/18
06/01/18
UPGRADE
Target $15.75

Outperform
Navient upgraded to Outperform with $15.75 price target at Wedbush
As previously reported, Wedbush analyst Henry Coffey upgraded Navient to Outperform from Neutral, stating that the company's new reporting structure helps him better appreciate the company's earnings outlook and suggests the company is likely to report modest growth in EPS and a total return of over 18% during the next 18 months. Coffey raised his estimates for Navient and increased his price target on the stock to $15.75 from $14.50.
04/05/18
COMP
04/05/18
UPGRADE
Target $15.5
COMP
Buy
Navient upgraded to Buy from Neutral at Compass Point
Compass Point analyst Mike Tarkan upgraded Navient to Buy from Neutral, as he believes improving credit trends, an increasing mix towards refi loans, and lower provision expenses can drive earnings higher over the next several years. He also thinks the private student loan portfolio may hit an inflection point in late 2020 and resume growth from there. Tarkan maintains a $15.50 price target on Navient shares.
04/04/18
COMP
04/04/18
UPGRADE
COMP
Buy
Navient upgraded to Buy from Neutral at Compass Point
06/01/18
WEDB
06/01/18
UPGRADE
WEDB
Outperform
Navient upgraded to Outperform from Neutral at Wedbush
NFLX Netflix
$338.98

-2.3 (-0.67%)

08/13/18
IMPC
08/13/18
NO CHANGE
Target $494
IMPC
Outperform
Netflix price target lowered to $494 from $503 at Imperial Capital
Imperial Capital analyst David Miller lowered his price target for Netflix to $494 after slightly reducing his global subscriber estimates. The analyst says that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. Miller, however, keeps an Outperform on the shares. He believes Netflix can afford to be patient with original programming and that "in reality, there is not much competition" for the company.
08/13/18
KEYB
08/13/18
NO CHANGE
Target $375
KEYB
Overweight
KeyBanc sees minimal disruption for Netflix from CFO exit
KeyBanc analyst Andy Hargreaves says that while the departure of CFO David Wells is a loss, he expects minimal disruption since Netflix's "financial strategy is now well established." Further, the company "should attract excellent candidates that are capable of ramping quickly," Hargreaves tells investors in a research note titled "CFO Departure Should Not Be a Material Negative." The analyst sees little in Wells' departure to change his view of long-term value in Netflix. Hargreaves keeps an Overweight rating on the shares.
08/14/18
COWN
08/14/18
NO CHANGE
Target $400
COWN
Outperform
Netflix CFO change should be smooth transition, says Cowen
Cowen analyst John Blackledge noted Netflix announced its CFO will step down following the search for a replacement. He believes the search is in its early stages and that the transition will be smooth without any foreseeable material change to the business. Blackledge reiterated his Outperform rating and $400 price target on Netflix shares.
08/13/18
08/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN SACHS CUTS ALNYLAM TO BUY: Goldman Sachs analyst Terence Flynn downgraded Alnylam (ALNY) to Buy from Conviction Buy. The analyst also lowered his price target for the shares to $155 from $193. Flynn said the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. Piper Jaffray analyst Edward Tenthoff recommended buying shares of Alnylam Pharmaceuticals on weakness following the approval of Onpattro. Morgan Stanley analyst David Lebowitz lowered his price target to $93, Nomura Instinet analyst Christopher Marai lowered his price target to $73, and Stifel analyst Paul Matteis maintained a Buy rating but cut his price target to $123 from $125 and slightly lowered his revenue ramp for the drug based on modestly reduced share in mixed-phenotype haTTR patients and lower share in cardiac-only haTTR patients. B. Riley FBR analyst Madhu Kumar raised his price target to $230. RUBIUS THERAPEUTICS INITIATED AT MULTIPLE FIRMS: Rubius Therapeutics (RUBY) was initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. PIPER JAFFRAY SAYS AMAZON AD BUSINESS GROWING INTO PROFIT DRIVER: Amazon's (AMZN) advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson told investors in a research note. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contended. IMPERIAL CAPITAL CUTS NETFLIX PRICE TARGET TO $494: Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $494 after he slightly reduced his global subscriber estimates. The analyst said that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. DISH DOWNGRADED TO SELL AT MOFFETTNATHANSON: MoffettNathanson analyst Craig Moffett downgraded Dish (DISH) to Sell from Neutral with a price target of $29 and noted that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse.
NYB New York Community Bancorp
$0.00

(0.00%)

SBGI Sinclair Broadcast
$28.45

0.6 (2.15%)

07/19/18
SPHN
07/19/18
DOWNGRADE
Target $37
SPHN
Equal Weight
Tribune Media downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Kyle Evans downgraded Tribune Media (TRCO) to Equal Weight from Overweight after the FCC announced last night that it has adopt a Hearing Designation Order for the Sinclair Broadcast (SBGI) deal. He had hoped the revised divestiture plan would eliminate the need for an HDO, but now that it has been adopted he is more worried that there could be character issues standing in the way of the deal being closed. Evans lowered his price target on Tribune shares to $37 from $41.
07/27/18
WELS
07/27/18
NO CHANGE
WELS
DOJ broadcast investigation unlikely to be material, says Wells Fargo
Wells Fargo analyst Marci Ryvicker says her conversions with industry contacts indicate the Department of Justice investigation into various television groups for alleged ad-rate collusion is unlikely to be material. The investigation likely stemmed from the DOJ's review of the Sinclair Broadcast (SBGI), Tribune Media merger, Ryvicker tells investors in a research note. She believes high levels of conversations about business likely drove the investigation and that it will be tough to prove that this lead to price fixing.
07/27/18
SPHN
07/27/18
NO CHANGE
SPHN
Reported DOJ investigation likely to pressure broadcaster stocks, says Stephens
After The Wall Street Journal reported yesterday that the Department of Justice is investigating whether TV station owners violated antitrust law in ways that inflated local ad prices, Stephens analyst Kyle Evans said that the negative news is likely to further pressure a group that he sees being "hard to own in any quarter." Evans added that, in his view, any miss within the group seems to drag them all down. Publicly traded broadcasters include Sinclair (SBGI), Tribune Media (TRCO), Gray Television (GTN), Nexstar (NXST) and Tegna (TGNA).
07/31/18
EVER
07/31/18
INITIATION
Target $34
EVER
In Line
Sinclair Broadcast initiated with an In Line at Evercore ISI
Evercore ISI analyst David Joyce initiated Sinclair Broadcast with an In Line and $34 price target.
HUM Humana
$329.23

5.245 (1.62%)

08/02/18
RBCM
08/02/18
NO CHANGE
Target $318
RBCM
Sector Perform
Humana price target raised to $318 from $278 at RBC Capital
RBC Capital analyst Frank Morgan raised his Humana price target to $318 after its Q2 results, saying the company "again exceeded expectations with solid membership growth and lower-than-expected medical costs". The analyst is also positive on the company's visibility and the management's initiative in the rollout of integrated care strategy, while "maintaining optionality" on partnership-driven strategic alignment. Morgan sees "significant tailwinds" supporting Humana's earnings growth, but keeps his Sector Perform rating given the valuation on the stock.
08/02/18
RHCO
08/02/18
NO CHANGE
Target $350
RHCO
Hold
Humana price target raised to $350 from $330 at SunTrust
SunTrust analyst David MacDonald raised his price target on Humana to $350 after its "solid" Q2 results, driven by "attractive core trends, better than expected MCR, and a strong performance in Retail". The analyst adds that the company has plenty of positives such as Medicare Advantage presence, growing Medicaid business, and Healthcare Services but keeps his Hold rating on "balanced" risk-reward at its current valuation.
07/12/18
MSCO
07/12/18
INITIATION
Target $362
MSCO
Overweight
Humana resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak resumed coverage of Humana with an Overweight rating and $362 price target, stating that he believes the company's leading position in Medicare Advantage puts it in an "enviable growth position."
07/06/18
PIPR
07/06/18
NO CHANGE
Target $350
PIPR
Overweight
Humana price target raised to $350 from $326 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Humana to $350 after unceasing her 2019 estimates to better reflect her long-term growth thesis in Medicare Advantage. The analyst keeps an Overweight rating on the shares.
TRN Trinity Industries
$37.42

0.06 (0.16%)

06/28/18
MZHO
06/28/18
INITIATION
MZHO
Buy
Trinity Industries initiated with a Buy at Mizuho
06/29/18
MZHO
06/29/18
INITIATION
Target $42
MZHO
Buy
Trinity Industries initiated with a Buy at Mizuho
Mizuho analyst Kristine Kubacki started Trinity Industries (TRN) with a Buy rating and $42 price target. Improved freight traffic, lower railroad service performance and improving lease rates means the cycle is taking back off, Kubacki tells investors in a research note. Further, the analyst believes Trinity's impending spin-off of Arcosa will yield higher focus and visibility on its rail assets. She believes Trinity's lease portfolio trades at a "meaningful discount" to publicly-traded peer GATX (GATX).
04/26/18
VERF
04/26/18
NO CHANGE
VERF
Sell
Vertical Group recommends shorting Trinity Industries strength
Vertical Group analyst Gordon Johnson II believes Trinity Industries' FY18 EPS guidance increase of 5c per share is due entirely to higher expected spin-off related costs, which he notes are excluded from the company's view, rather than an improvement in fundamentals. Adding that the company's margins are getting worse, both sequentially and year-over-year, in Trinity's two key business segments, the analyst recommends shorting any strength in the stock today and keeps a Sell rating on Trinity shares.
03/06/18
VERF
03/06/18
INITIATION
Target $20
VERF
Sell
Trinity Industries initiated with a Sell at Vertical Group
Vertical Group analyst Gordon Johnson started Trinity Industries with a Sell rating and $20 price target.
C Citi
$69.79

0.66 (0.95%)

07/27/18
RHCO
07/27/18
NO CHANGE
Target $240
RHCO
Buy
MasterCard price target raised to $240 from $215 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard to $240 and kept his Buy rating, saying the company is demonstrating expansion of global market share while posting a 14% Q2 volume growth. The analyst adds that while MasterCard has a higher valuation than PayPal (PYPL) and Visa (V) - a 10% relative EBITDA premium - it is justified and may even be too narrow given its superior growth sustainability and margin upside.
06/29/18
OPCO
06/29/18
NO CHANGE
Target $88
OPCO
Outperform
Oppenheimer says 'particularly pleased' with Citi's $17.6B share buyback
Following the release of CCAR results for 2018, Oppenheimer analysts Chris Kotowski and Ben Chittenden told investors in a research note that they are "particularly pleased" with Citi's (C) $17.6B share buyback, up 13% from last year and above their $16.5B estimate, while the dividend increase to 45c was also 5c better than expected. The analysts noted that both Goldman (GS) and Morgan Stanley (MS) got "conditional passes" on their capital plans, as both banks "ran a bit afoul" of the supplementary leverage ratio limitation.
07/16/18
BMOC
07/16/18
NO CHANGE
Target $85
BMOC
Market Perform
Citi price target raised to $85 from $76 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Citi to $85 after its Q2 earnings beat that was driven by better than expected investment banking and credit growth. The analyst also states that Citi's Q2 capital markets-related revenues were higher than expected, while the provisions for loan losses were lower than previously modeled. Fotheringham notes that Citi stock is "cheap again" following a 10% year-to-date decline, trading at only a 6.8-times two-year forward core earnings relative to its 9.5-times historical multiple.
FTSI FTS International
$12.16

0.09 (0.75%)

08/02/18
FBCO
08/02/18
NO CHANGE
Target $15
FBCO
Outperform
FTS International price target lowered to $15 from $26 at Credit Suisse
Credit Suisse analyst James Wicklund lowered his price target for FTS International to $15 from $26 after the company reported a missed quarter, with crews being released by a few different customers in the Marcellus as budgets ran out and completion efficiency put production ahead of schedule, guiding Q3 down on crews, revenues and margins, while acknowledging plans to increase activity in Q4. The analyst reiterates an Outperform rating on the shares.
06/29/18
WELS
06/29/18
DOWNGRADE
Target $27
WELS
Market Perform
U.S. Silica downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Judson Bailey downgraded U.S. Silica (SLCA) to Market Perform and lowered his price target for the shares to $15 from $20. Downside risk for completion activity over the next few quarters and negative pricing and demand data points already rolling in for pressure pumping create risk to consensus estimates, Bailey tells investors in a research note. The analyst believes the pressure pumping market is already weakening. Bailey this morning also downgraded shares of C&J Energy Services (CJ), FTS International (FTSI) and Keane Group (FRAC).
06/29/18
WELS
06/29/18
DOWNGRADE
Target $17
WELS
Market Perform
FTS International downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Judson Bailey downgraded FTS International to Market Perform and lowered his price target for the shares to $17 from $27. Downside risk for completion activity over the next few quarters and negative pricing and demand data points already rolling in for pressure pumping create risk to consensus estimates, Bailey tells investors in a research note. The analyst believes the pressure pumping market is already weakening.
07/25/18
SOCO
07/25/18
INITIATION
Target $15
SOCO
Equalweight
FTS International initiated with an Equalweight at Capital One
Capital One initiated FTS International with an Equal Weight and $15 price target.
SHPG Shire
$169.65

-0.13 (-0.08%)

04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
ANDV Andeavor
$149.29

0.45 (0.30%)

05/18/18
TUDR
05/18/18
DOWNGRADE
TUDR
Hold
Andeavor downgraded to Hold from Buy at Tudor Pickering
08/14/18
RBCM
08/14/18
NO CHANGE
Target $151
RBCM
Sector Perform
Andeavor price target raised to $151 from $137 at RBC Capital
RBC Capital analyst Brad Heffern raised his price target on Andeavor (ANDV) to $151 after its "solid" Q2 earnings beat driven by stronger throughput margin. The analyst also notes that the company's strategic combination with Marathon Petroleum (MPC) remains on track to close on October 1st. Based on the current valuation of that acquisition relative to their previously agreed share exchange ratio, Heffern keeps his Sector Perform rating on Andeavor.
06/29/18
USCA
06/29/18
DOWNGRADE
USCA
Hold
Andeavor downgraded to Hold from Buy at US Capital Advisors
MXL MaxLinear
$19.19

0.05 (0.26%)

06/11/18
ROTH
06/11/18
DOWNGRADE
Target $20
ROTH
Neutral
MaxLinear downgraded to Neutral on near-term headwinds at Roth Capital
Roth Capital analyst Suji Desilva downgraded MaxLinear to Neutral from Buy and lowered his price target for the shares to $20 from $27. While the company remains positioned for the intermediate-term ramps of wireless infrastructure and connected home, near-term headwinds will impact its outlook, Desilva tells investors in a research note. The analyst believes China infrastructure concerns, a step back in multimedia over coax alliance connectivity demand and continued terrestrial tuner demand softness will limit upside in shares of MaxLinear in the short term. He will look for improving visibility prior to getting more aggressive with the stock.
07/18/18
DBAB
07/18/18
NO CHANGE
Target $19
DBAB
Hold
MaxLinear Q2 likely to be at lower end of guidance, says Deutsche Bank
Deutsche Bank analyst Ross Seymore believes headwinds within MaxLinear's (MXL) Connected Home segment are likely to yield Q2 results toward the lower end of guidance and Q3 revenues that are likely to slightly decline quarter-over-quarter. Further, the analyst believes the transition from DOCSIS 3.0 to DOCSIS 3.1 has been delayed at Arris (ARRS), MaxLinear's largest customer, thereby creating an additional headwind for Q2 and Q3. Seymore lowered his estimates for MaxLinear and expects the stock to remain range-bound. The analyst cut his price target for the stock to $19 from $21 and keeps a Hold rating on the name.
07/12/18
BNCH
07/12/18
NO CHANGE
BNCH
Buy
Marvell, Ceva, MaxLinear stand to benefit from ZTE ban ending, says Benchmark
After the U.S. announced it has signed an escrow agreement with ZTE (ZTCOY) that should lift the supplier ban and allow the company to resume operations, Benchmark analyst Gary Mobley identified Ceva (CEVA), Marvell Technology (MRVL) and MaxLinear (MXL) as the stocks that he covers that have the most to gain from the lifting of the ZTE shipment ban. He maintains Buy ratings on all three suppliers.
06/29/18
NEED
06/29/18
NO CHANGE
Target $22
NEED
Buy
MaxLinear price target lowered to $22 from $27 at Needham
Needham analyst N. Quinn Bolton lowered his price target on MaxLinear to $22, saying the company is "hitting air pockets" in its cable data business amid transition issues between DOCSIS 3.0 and DOCSIS 3.1. Bolton states that the purchases of the former are down as OEMs look to reduce their inventory levels, while the ramp of the latter is taking longer and is now expected to start in Q4. The analyst keeps his Buy rating on MaxLinear longer term, noting that the DOCSIS weakness is already reflected in the price after the recent selloff.
PVH PVH Corp.
$153.26

0.02 (0.01%)

06/26/18
FBCO
06/26/18
NO CHANGE
Target $185
FBCO
Outperform
PVH Corp. price target raised to $185 from $178 at Credit Suisse
Credit Suisse analyst Michael Binetti raised his price target for PVH Corp. to $185 from $178 as he has increased conviction that it can easily beat plan in 2018. Guide implies a significant revenue slowdown, but the analyst sees no reason why trends would slow amid ongoing global momentum, new growth sources, and visible share donors. He reiterates an Outperform rating on the shares.
06/25/18
GSCO
06/25/18
INITIATION
GSCO
Sell
PVH Corp. initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis initiated PVH Corp (PVH) with a Sell, telling investors in a research note that while the company has benefited from a strong acceleration in growth in Tommy Hilfiger and Calvin Klein, she believes momentum is peaking as a number of tailwinds fade. This morning, Walvis also initiated shares of Tapestry (TPR) with a Conviction Buy and Tiffany (TIF) and VFC (VFC) with a Buy.
06/25/18
GSCO
06/25/18
INITIATION
GSCO
Buy
VF Corp. initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis initiated VFC Corp (VFC) with a Buy rating, telling investors in a research note that VFC is an "under-appreciated growth asset," with brands with momentum like Vans and "credible" turnaround potential like Wrangler and The North Face, many of which have opportunities for channel shift enabled by digital. The analyst says she is "enthusiastic" about opportunities to deploy cash given VFC's strong balance sheet and expertise in integrating acquisitions. This morning, Walvis also initiated shares of Tapestry (TPR) with a Conviction Buy, Tiffany (TIF) with a Buy and PVH (PVH) with a Sell.
06/25/18
06/25/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twilio (TWLO) initiated with an Overweight at Piper Jaffray. 2. Albemarle (ALB) initiated with a Buy at BofA/Merrill. 3. PVH Corp. (PVH) initiated with a Sell at Goldman Sachs. 4. New Relic (NEWR) initiated with a Buy at Deutsche Bank. 5. Alibaba (BABA) initiated with a Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DISH Dish
$35.50

0.5 (1.43%)

08/13/18
MOFT
08/13/18
DOWNGRADE
Target $29
MOFT
Sell
Dish downgraded to Sell at MoffettNathanson on deteriorating spectrum
As reported earlier, MoffettNathanson analyst Craig Moffett downgraded Dish to Sell from Neutral with a price target of $29. The analyst notes that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment - which holds "all" of the company's equity value - is worse. Moffett states that all considerations for the business aside from Spectrum sale, including the network buildout, is a negative for Dish, adding that the Q2 report has only made the "other scenarios more likely".
08/13/18
MOFT
08/13/18
DOWNGRADE
MOFT
Sell
Dish downgraded to Sell from Neutral at MoffettNathanson
08/13/18
08/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Rite Aid (RAD) downgraded to Market Perform from Outperform at Cowen with analyst Charles Rhyee saying shares of Ride Aid adequately reflect its outlook, following the termination of the company's merger with Albertsons. 2. Akamai (AKAM) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick saying with the stock up 29% since Elliott Management's disclosure of a stake on December 15, 2017, many of the catalysts have played out. 3. Alnylam (ALNY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. 4. Goodyear Tire (GT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying he remains "constructive" on the long-term growth for global miles traveled, but believes this will not affect the stock for the next 12 months due to the overhang from estimate achievability. 5. Dish (DISH) downgraded to Sell from Neutral at MoffettNathanson with analyst Craig Moffett saying while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
UAL United Continental
$82.15

0.89 (1.10%)

08/08/18
MSCO
08/08/18
NO CHANGE
Target $67
MSCO
Overweight
Southwest would be good strategic fit for Berkshire, says Morgan Stanley
Morgan Stanley analyst Kai Pan noted that Berkshire Hathaway (BRK.A) has shifted tone in recent years and become a top three shareholder of the "Big Four" U.S. airlines, including Southwest (LUV). Media reports from Forbes, CNN and others have discussed a possible acquisition by Berkshire of the airline, added Pan, who said he has no knowledge of any M&A discussions and noted that the airlines have not commented. Given that background, he analyzed a theoretical acquisition and came to the conclusion that Southwest could be a strategic fit for Berkshire and the advantages could also be compelling for the airline. Pan estimates Berkshire could pay a 20-40% premium, or $70-80 per share for Southwest, in such a hypothetical takeover situation, in which he also thinks Berkshire would divest its current holdings in American Airlines (AAL), Delta (DAL) and United Continental (UAL). Pan has an Overweight rating and $67 price target on Southwest shares.
07/19/18
BUCK
07/19/18
NO CHANGE
Target $106
BUCK
Buy
United Continental price target raised to $106 from $96 at Buckingham
Buckingham analyst Daniel McKenzie raised his price target on United Continental to $106 and kept his Buy rating after its better than expected Q2 unit revenue and Q3 outlook. The analyst says the management "succinctly articulated a "no-excuses" EPS goal of $11-$13 in 2020", adding that even in the event of an economic downturn, the airline has "plenty of capacity flexibility". McKenzie further notes that United Continental's raised earnings guidance "adds credibility" to the business plan, stating he is confident that the airline can continue executing on top-line growth, with industry supply up just 2.9% and demand on the rise.
07/19/18
07/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Neutral at Credit Suisse WITH analyst Paul Condra saying he believes its growing product eco-system is increasing its ability to penetrate larger merchants, positive data points on Cash-App adoption validate Square's two-sided platform strategy to grow both merchant and consumer use-cases, and growth investing should support strong revenue trends driving upside to revenue forecasts in the out-years. 2. Discovery (DISCA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Drew Borst saying Discovery's acquisition of Scripps creates "meaningful" cost and revenue synergy opportunities. 3. Grainger (GWW) upgraded to Neutral from Sell at UBS with analyst Steven Winoker saying the company's strategic initiatives, including its pricing reset and e-commerce platform development, reposition it to gain market share through 2019. 4. Hilton (HLT) upgraded to Buy from Hold at Berenberg. 5. United Continental (UAL) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/18
MACQ
07/19/18
UPGRADE
Target $95
MACQ
Outperform
United Continental upgraded to Outperform on continued execution at Macquarie
As previously reported, Macquarie upgraded United Continental to Outperform from Neutral with a $95 price target. Analyst Susan Donofrio said United is demonstrating its ability to execute on commercial initiatives following another beat and raise quarter and demonstrates its earnings growth ability in a rising fuel environment.
GOOG Alphabet
$1,234.94

-0.16 (-0.01%)

08/09/18
STFL
08/09/18
DOWNGRADE
Target $2150
STFL
Hold
Booking Holdings downgraded to Hold on slowing growth at Stifel
As previously reported, Stifel analyst Scott Devitt downgraded Booking Holdings (BKNG) to Hold from Buy, citing the slowing growth at the company-formerly-known-as Priceline. Devitt lowered his core bookings growth expectations in 2018 and beyond following the company's Q2 earnings report and cut his price target on Booking shares to $2,150 from $2,332. He sees better large cap opportunities at company's with similar earnings multiples and better growth, such as Alibaba (BABA), Alphabet (GOOGL) and Facebook (FB), Devitt added.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/07/18
08/07/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS ZILLOW TO NEUTRAL: BofA Merrill Lynch analyst Nat Schindler downgraded Zillow (Z, ZG) to Neutral from Buy and cut its price target to $60 from $70 following the Q2 report and reduction in guidance. Schindler said the quarter indicated Zillow is taking longer than expected to ramp up the Homes business, Rentals revenue missed and the outlook was cut, and other revenue also missed, indicating the new construction opportunity is also taking longer to materialize. Zillow Class A shares are down about 17% in late morning trading. MORGAN STANLEY SAYS WAYMO COULD BE WORTH $175B: Morgan Stanley analyst Brian Nowak increased his enterprise value estimate for Alphabet's (GOOG, GOOGL) Waymo unit from $75B for ride sharing only to $175B given his analyses for two other emerging business models, logistics and licensing. He believes Waymo remains on track to launch an autonomous ride hailing service in Phoenix this year and believes this business could be worth about $80B over the long-term. Given his view of Waymo being a key part of Alphabet's long-term value, Nowak raised his sum of the parts valuation to $1,550 from $1,400. He has an Overweight rating and $1,325 price target on Alphabet shares. GOLDMAN RAISES NVIDIA TARGET AHEAD OF EARNINGS: Goldman Sachs analyst Toshiya Hari raised his price target for Nvidia (NVDA) to $324 from $310 ahead of quarterly results. Unlike the past 10 quarters where the company handily beat Street estimates and raised guidance, the analyst expects a "noisy" quarter with the focal points being the upcoming product transition in Gaming, the current product transition in Datacenter, weakness in cryptocurrency mining, and potential disruption from the virus attack at TSMC (TSM). That said, Hari noted that his long-term bull thesis on Nvidia remains intact and reiterated a Buy rating on the shares. ARGUS CUTS CBS TO HOLD: Argus analyst Joseph Bonner downgraded CBS (CBS) to Hold from Buy, noting significant downside risks for the company from both the sexual harassment allegations against CEO Moonves and the board's attempts to prevent the Viacom (VIA, VIAB) merger. Bonner noted that if the Moonves allegations are proven true, he would be immediately dismissed, which could end the board's bid to remain independent and thereby inflict damage on the shareholders.
08/07/18
MSCO
08/07/18
NO CHANGE
Target $1325
MSCO
Overweight
Enterprise value of Alphabet's Waymo raised to $175B at Morgan Stanley
Morgan Stanley analyst Brian Nowak increased his enterprise value estimate for Alphabet's Waymo unit from $75B for ride sharing only to $175B given his analyses for two other emerging business models, namely logistics and licensing. He believes Waymo remains on track to launch an autonomous ride hailing service in Phoenix this year and believes this business could be worth about $80B over the long-term. Partnerships with Walmart (WMT), DDR (DDR) and Peterbilt speak to Waymo's logistics focus, said Nowak, who sees the company potentially having a $90B logistics business. Additionally, he sees a roughly $7B licensing opportunity, pointing to the company's FCA (FCAU) relationship as a model of how companies could pay a license fee to Waymo for its autonomous technology. Given his view of Waymo being a key part of Alphabet's long-term value, Nowak raised his sum of the parts valuation to $1,550 from $1,400. He has an Overweight rating and $1,325 price target on Alphabet shares.
GOOGL Alphabet Class A
$1,249.88

1.12 (0.09%)

AMCX AMC Networks
$61.11

1.12 (1.87%)

06/26/18
GSCO
06/26/18
DOWNGRADE
GSCO
Neutral
AMC Networks downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Drew Borst downgraded AMC Networks to Neutral and maintained a $70 price target. Borst said slowing advertising growth due to rating headwinds from The Walking Dead franchise and affiliate fee growth challenges in the pay TV ecosystem are a risk to earnings estimates.
06/21/18
06/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Neutral from Buy at UBS with analyst Jay Sole saying Nike's "comeback after two relatively down years continues." 2. Infinera (INFN) downgraded to Neutral from Buy at Goldman Sachs with analyst Rod Hall assumed coverage from Doug Clark and downgrading the stock to Neutral from Buy while saying the company's success is dependent on the new products, while its "key higher TAM products are yet to fully hit the market." 3. AMC Networks (AMCX) downgraded to Underperform from Market Perform at Bernstein with analyst Todd Juenger saying he thinks it is unlikely the company will be acquired at a premium. 4. Catalyst Biosciences (CBIO) downgraded to Neutral from Buy at B. Riley FBR. 5. Noble Corp. (NE) downgraded to Hold from Buy at Jefferies with analyst Eduardo Royes saying the stock is up 18% year-to-date versus its four major peers rising only 2%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/18
IMPC
07/19/18
INITIATION
Target $65
IMPC
In-Line
AMC Networks initiated with an In-Line at Imperial Capital
Imperial Capital analyst David Miller started AMC Networks with an In-Line rating and $65 price target. AMC is not really a "pure content provider," due to only four series currently on air that are actually owned by AMC Studios, the analyst tells investors in a research note. He's concerned about what will happen to AMCX's other networks such as Sundance, WE Network, and IFC, networks that are not considered "must have" as consumers migrate towards skinnier packages.
06/26/18
06/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Underperform from Market Perform at Bernstein with analyst Stacy Rasgon saying she sees the CEO change and leadership vacuum providing some protection from further upward revisions, EPS growth slowing into 2019 as compares get harder and structural issues build, and an increasingly competitive environment. 2. LendingTree (TREE) downgraded to Neutral from Buy at Compass Point with analyst Michael Tarkan citing mortgage deceleration and remaining long-term cycle risks. 3. AMC Networks (AMCX) downgraded to Neutral from Buy at Goldman Sachs with analyst Drew Borst saying slowing advertising growth due to rating headwinds from The Walking Dead franchise and affiliate fee growth challenges in the pay TV ecosystem are a risk to earnings estimates. 4. Square (SQ) downgraded to Equal Weight from Overweight at Stephens with analyst Brett Huff stating that after a "truly remarkable" stock price acceleration over the past two years, he thinks Square is a "special" company, but is taking a breather. 5. Incyte (INCY) downgraded to Sector Perform from Outperform at RBC Capital with analyst Brian Abrahams noting that as he previously suggested, the market overreacted to the setbacks suffered by the company's epacadostat and baricitini programs when he also forecasted a rally to reflect the "substantial Jakafi growth opportunity through its out-year patent cliff". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FDC First Data
$24.18

0.28 (1.17%)

07/31/18
CHLM
07/31/18
NO CHANGE
Target $35
CHLM
Buy
First Data price target raised to $35 from $30 at Craig-Hallum
Craig-Hallum analyst Bradley Berning raised his price target for First Data to $35 from $30 saying the revenue acceleration is closing the gap to peers. The analyst reiterates a Buy rating on the shares.
07/31/18
CANT
07/31/18
NO CHANGE
Target $23
CANT
Neutral
First Data price target raised to $23 from $17 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for First Data to $23 citing an acceleration in organic growth following the company's Q2 results. He keeps a Neutral rating on the shares, however, which is based on the company's "below-industry growth rate and comparative leverage."
07/17/18
WOLF
07/17/18
INITIATION
Target $30
WOLF
Outperform
First Data initiated with an Outperform at Wolfe Research
Wolfe Research analyst Darrin Peller initiated First Data with an Outperform and $30 price target.
07/19/18
MSCO
07/19/18
NO CHANGE
MSCO
Morgan Stanley upgrades Payments and Processing industry to Attractive
Morgan Stanley analyst James Faucette upgraded his view of the Payments and Processing industry to Attractive, citing the firm's U.S. Strategy Team's call for rotation out of Technology and his view that Payments will be seen as an attractive option for investors looking to become more defensive. Investors underappreciate the resilience of consumer spending and Faucette sees the potential for his Payments coverage market-cap weighted earnings growth to accelerate organically to 15% over 2018-2020 from 11% growth over the last three years, he tells investors. In the group, the firm has Overweight ratings on Visa (V), MasterCard (MA), PayPal (PYPL), GreenSky (GSKY), Worldpay (WP) and FleetCor (FLT). Morgan Stanley has Underweight ratings on Western Union (WU) and On Deck Capital (ONDK), having downgraded On Deck this morning.
MSFT Microsoft
$109.40

1.16 (1.07%)

07/23/18
ARGS
07/23/18
NO CHANGE
Target $128
ARGS
Buy
Microsoft price target raised to $128 from $116 at Argus
Argus analyst Joseph Bonner raised his price target on Microsoft to $128 and kept his Buy rating after the company's "strong quarter" in Q4 and positive comments about FY19. The analyst believes the company is well positioned to grow its commercial revenue amid the accelerating digital transformation trend thanks to its "massive" user base and long-term relationships. Despite the run-up in the stock price, the analyst contends that Microsoft shares could move even higher as the company's commercial and public cloud business drive growth.
07/27/18
OPCO
07/27/18
NO CHANGE
Target $120
OPCO
Outperform
Microsoft price target raised to $120 from $115 at Oppenheimer
Oppenheimer analyst Tim Horan raised his price target on Microsoft (MSFT) to $120 and maintained an Outperform rating, telling investors in a research note that he remains "bullish." With enterprises in the steepest part of the S-curve adoption cycle of cloud, over the next few quarters, he says he expects strong results from Azure which benefits from AWS (AMZN)/Google (GOOG, GOOGL) channel conflicts and also sees upside surprises in Gaming, Search, Dynamics, Hardware and strong operating leverage.
08/03/18
BARD
08/03/18
NO CHANGE
Target $2100
BARD
Outperform
Amazon summit highlights long cloud growth runway, says Baird
After having attended the AWS Summit in Chicago this week, Baird analyst Colin Sebastian said his talks with several enterprise IT decision makers highlight Amazon's "clear advantage" in product breadth and go-to-market capabilities despite the fact that cloud services competition is "undoubtedly intensifying" from Microsoft's (MSFT) Azure and Alphabet's (GOOGL) Google Cloud Platform. Most large-scale enterprises are still in the early days of cloud migration, which bodes well for the long-term growth outlook for AWS along with Azure and Google Cloud, Sebastian concluded. He keeps an Outperform rating and $2,100 price target on Amazon shares.

TODAY'S FREE FLY STORIES

14:20
12/18/18
12/18
14:20
12/18/18
14:20
General news
Canada CPI preview »

Canada CPI preview:…

TCEHY

Tencent

$0.00

(0.00%)

, DIS

Disney

$109.75

-0.88 (-0.80%)

14:18
12/18/18
12/18
14:18
12/18/18
14:18
Periodicals
'PUBG' on mobile has as many total users as 'Fortnite,' Verge reports »

The mobile version of…

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$109.75

-0.88 (-0.80%)

KKR

KKR

$19.89

0.09 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/18/18
12/18
14:17
12/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/18/18
12/18
14:16
12/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.72

-0.39 (-5.49%)

14:05
12/18/18
12/18
14:05
12/18/18
14:05
Options
McDermott call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$163.24

-0.19 (-0.12%)

14:02
12/18/18
12/18
14:02
12/18/18
14:02
Hot Stocks
General Dynamics unit awarded Department of Education contract »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

APHA

Aphria

$5.87

0.43 (7.90%)

, TLRY

Tilray

$76.52

10.63 (16.13%)

14:00
12/18/18
12/18
14:00
12/18/18
14:00
Hot Stocks
Citron touts cannabis name Aphria again, sees shares above $8 by year-end »

Shares of Aphria (APHA)…

APHA

Aphria

$5.87

0.43 (7.90%)

TLRY

Tilray

$76.52

10.63 (16.13%)

ACB

Aurora Cannabis

$5.57

0.03 (0.54%)

MO

Altria Group

$51.40

-0.97 (-1.85%)

NVS

Novartis

$85.56

-0.24 (-0.28%)

CRON

Cronos Group

$11.50

0.375 (3.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 07

    Feb

STZ

Constellation Brands

$172.45

-3.61 (-2.05%)

13:55
12/18/18
12/18
13:55
12/18/18
13:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MU

Micron

$34.81

0.92 (2.71%)

, UMC

UMC

$1.81

-0.005 (-0.28%)

13:50
12/18/18
12/18
13:50
12/18/18
13:50
On The Fly
Fly Intel: What to watch for in Micron's earnings report »

Micron (MU) is scheduled…

MU

Micron

$34.81

0.92 (2.71%)

UMC

UMC

$1.81

-0.005 (-0.28%)

INTC

Intel

$48.04

0.95 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 04

    Jan

  • 07

    Jan

  • 08

    Jan

VOD

Vodafone

$19.88

-0.13 (-0.65%)

13:48
12/18/18
12/18
13:48
12/18/18
13:48
Periodicals
Vodafone preparing to remove PwC as auditor, Sky News reports »

Vodafone is preparing to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

, GOOG

Alphabet

$1,046.01

28.41 (2.79%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Periodicals
Search engine startup claims Google still blocking competition, TechCrunch says »

The European Commission…

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

GOOG

Alphabet

$1,046.01

28.41 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KMX

CarMax

$60.38

0.11 (0.18%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Options
7X average daily option volume in CarMax driven by an earnings hedge »

7X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

  • 31

    Jan

  • 01

    Feb

BIDU

Baidu

$169.94

0.03 (0.02%)

13:35
12/18/18
12/18
13:35
12/18/18
13:35
Hot Stocks
Unity Technologies, Baidu partner to develop autonomous vehicle simulation »

Unity Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$131.11

2 (1.55%)

13:32
12/18/18
12/18
13:32
12/18/18
13:32
Periodicals
J&J settles woman's talc cancer case for over $1.5M, Bloomberg reports »

Johnson & Johnson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 27

    Jan

ORGS

Orgenesis

$4.84

-0.11 (-2.22%)

13:31
12/18/18
12/18
13:31
12/18/18
13:31
Hot Stocks
Orgenesis announces collaboration with MangoGen Pharma »

Orgenesis announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNN

Smith & Nephew

$36.67

-0.38 (-1.03%)

13:27
12/18/18
12/18
13:27
12/18/18
13:27
Hot Stocks
Smith & Nephew buys Ceterix Orthopaedics for $50M initial consideration »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALB

Albemarle

$81.62

1.12 (1.39%)

13:26
12/18/18
12/18
13:26
12/18/18
13:26
Hot Stocks
Albemarle higher after Hedgeye names new Best Idea Long »

Shares of Albemarle are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$104.09

1.87 (1.83%)

, ATVI

Activision Blizzard

$47.54

0.45 (0.96%)

13:24
12/18/18
12/18
13:24
12/18/18
13:24
On The Fly
Game On: Wedbush's Pachter says 'Red Dead 2' performing better than he expected »

SUCCESS OF 'RED DEAD 2':…

TTWO

Take-Two

$104.09

1.87 (1.83%)

ATVI

Activision Blizzard

$47.54

0.45 (0.96%)

EA

Electronic Arts

$81.22

2.01 (2.54%)

NTDOY

Nintendo

$0.00

(0.00%)

MSFT

Microsoft

$104.06

1.08 (1.05%)

SNE

Sony

$50.06

-0.425 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

  • 03

    Mar

  • 04

    Mar

13:20
12/18/18
12/18
13:20
12/18/18
13:20
Options
Put buying in PHLX Gold and Silver Mining Index as the sector sees strength »

Put buying in PHLX Gold…

APHA

Aphria

$5.98

0.54 (9.93%)

13:18
12/18/18
12/18
13:18
12/18/18
13:18
Hot Stocks
Citron expects 'major partnership or total buyout' soon for Aphria 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$6.01

0.57 (10.48%)

, IGC

India Globalization Capital

$0.00

(0.00%)

13:17
12/18/18
12/18
13:17
12/18/18
13:17
Hot Stocks
Citron mentions Aphria positively again, says 'everything changed' in cannabis 

Reference Link

APHA

Aphria

$6.01

0.57 (10.48%)

IGC

India Globalization Capital

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

CGC

Canopy Growth

$29.00

-0.365 (-1.24%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CRON

Cronos Group

$11.64

0.52 (4.68%)

TLRY

Tilray

$74.39

8.5 (12.90%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

ACB

Aurora Cannabis

$5.55

0.01 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$6.01

0.57 (10.48%)

13:17
12/18/18
12/18
13:17
12/18/18
13:17
Periodicals
Breaking Periodicals news story on Aphria »

Citron Research sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/18/18
12/18
13:17
12/18/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/18/18
12/18
13:16
12/18/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$24.98

-0.32 (-1.26%)

13:15
12/18/18
12/18
13:15
12/18/18
13:15
Options
Nielsen put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.